IO Biotech Inc
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand … Read more
IO Biotech Inc (IOBT) - Net Assets
Latest net assets as of September 2025: $911.00K USD
Based on the latest financial reports, IO Biotech Inc (IOBT) has net assets worth $911.00K USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($39.96 Million) and total liabilities ($39.05 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $911.00K |
| % of Total Assets | 2.28% |
| Annual Growth Rate | N/A |
| 5-Year Change | 1706.19% |
| 10-Year Change | N/A |
| Growth Volatility | 3497.06 |
IO Biotech Inc - Net Assets Trend (2019–2024)
This chart illustrates how IO Biotech Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for IO Biotech Inc (2019–2024)
The table below shows the annual net assets of IO Biotech Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $47.02 Million | -64.69% |
| 2023-12-31 | $133.16 Million | -4.10% |
| 2022-12-31 | $138.85 Million | -34.48% |
| 2021-12-31 | $211.92 Million | +8041.53% |
| 2020-12-31 | $2.60 Million | +276.95% |
| 2019-12-31 | $-1.47 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to IO Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 33295300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $66.00K | 0.14% |
| Other Comprehensive Income | $-6.85 Million | -14.57% |
| Other Components | $413.11 Million | 878.68% |
| Total Equity | $47.02 Million | 100.00% |
IO Biotech Inc Competitors by Market Cap
The table below lists competitors of IO Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Osia Hyper Retail Limited
NSE:OSIAHYPER
|
$6.89 Million |
|
Ekadharma International Tbk
JK:EKAD
|
$6.90 Million |
|
Study King Co., Ltd.
TWO:6780
|
$6.90 Million |
|
FACT II Acquisition Corp. Warrant
NASDAQ:FACTW
|
$6.90 Million |
|
Tamtron Group Oyj
HE:TAMTRON
|
$6.89 Million |
|
K-Tech Solutions Company Limited Class A Ordinary Shares
NASDAQ:KMRK
|
$6.89 Million |
|
Hamelin Gold Ltd
AU:HMG
|
$6.89 Million |
|
CIC39 Corp
VN:C32
|
$6.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in IO Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 133,162,000 to 47,015,000, a change of -86,147,000 (-64.7%).
- Net loss of 95,491,000 reduced equity.
- Other comprehensive income increased equity by 2,818,000.
- Other factors increased equity by 6,526,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-95.49 Million | -203.11% |
| Other Comprehensive Income | $2.82 Million | +5.99% |
| Other Changes | $6.53 Million | +13.88% |
| Total Change | $- | -64.69% |
Book Value vs Market Value Analysis
This analysis compares IO Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.25x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-8.30 | $0.18 | x |
| 2020-12-31 | $0.23 | $0.18 | x |
| 2021-12-31 | $7.35 | $0.18 | x |
| 2022-12-31 | $4.82 | $0.18 | x |
| 2023-12-31 | $3.06 | $0.18 | x |
| 2024-12-31 | $0.71 | $0.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently IO Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -203.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.44x
- Recent ROE (-203.11%) is below the historical average (-135.64%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.60 Million |
| 2020 | -462.62% | 0.00% | 0.00x | 2.17x | $-12.30 Million |
| 2021 | -32.03% | 0.00% | 0.00x | 1.05x | $-89.07 Million |
| 2022 | -51.46% | 0.00% | 0.00x | 1.09x | $-85.34 Million |
| 2023 | -64.65% | 0.00% | 0.00x | 1.13x | $-99.40 Million |
| 2024 | -203.11% | 0.00% | 0.00x | 1.44x | $-100.19 Million |
Industry Comparison
This section compares IO Biotech Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| IO Biotech Inc (IOBT) | $911.00K | 0.00% | 42.86x | $6.89 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |